We have located links that may give you full text access.
COMPARATIVE STUDY
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Sample size determination for phase II clinical trials based on Bayesian decision theory.
Biometrics 1998 March
This paper describes an application of Bayesian decision theory to the determination of sample size for phase II clinical studies. The approach uses the method of backward induction to obtain group sequential designs that are optimal with respect to some specified gain function. A gain function is proposed focussing on the financial costs of, and potential profits from, the drug development programme. On the basis of this gain function, the optimal procedure is also compared with an alternative Bayesian procedure proposed by Thall and Simon. The latter method, which tightly controls type I error rate, is shown to lead to an expected gain considerably smaller than that from the optimal test. Gain functions with respect to which Thall and Simon's boundary is optimal are sought and it is shown that these can only be of the form considered, that is, with constant cost for phase III study and cost of the phase II study proportional to the sample size, if potential profit increases over time.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app